ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1391

Possible Mechanistic Pathways of the Effective “Plants for Joints” Lifestyle and Dietary Intervention for Rheumatoid Arthritis

Carlijn Wagenaar1, Márcia Pereira2, Sylvio Redanz3, Arne Gessner4, Wendy Walrabenstein5, Martin Kriegel3, Mario Zaiss6 and Dirkjan van Schaardenburg7, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2University of Münster, Münster, Germany, 3Institute of Musculoskeletal Medicine, University of Münster, Department of Translational Rheumatology and Immunology, Münster, Germany, Münster, Germany, 4Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 5Reade Center for Rheumatology and Rehabilitation, Amsterdam, Netherlands, 6Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universittsklinikum Erlangen, Erlangen, Germany; 2 Deutsches Zentrum für Immuntherapie (DZI), Erlangen, Germany, 7Amsterdam UMC, Amsterdam, Netherlands

Meeting: ACR Convergence 2024

Keywords: diet, metabolomics, nutrition, physical activity, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The 16-week Plants for Joints (PFJ) intervention, consisting of a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease Activity Score (DAS28) in people with rheumatoid arthritis (RA) compared to standard care.1,2 The mucosal origins hypothesis suggests RA is triggered at mucosal sites in genetically predisposed individuals,3 and then transitions to the synovial joints.4 Also, studies indicate fiber ingestion supports gut barrier health, thereby reducing inflammation.5 This study aims to assess the integrity of the gut barrier and identify key metabolites, aiming to discover potential mechanistic pathways linking the intervention to its observed clinical effects.

Methods: Stool and blood samples were collected at baseline and 16 weeks. Fecal albumin and calprotectin levels were measured by ELISA in all 77 participants. Untargeted metabolomics were performed on plasma samples from 30 participants with the greatest DAS28 change during the intervention and 10 control group participants with stable DAS28 using high resolution mass spectrometry coupled to liquid chromatography. Between-group differences at 16-weeks in albumin and calprotectin were evaluated with linear regression adjusted for baseline values. Within-group differences and correlations with DAS28 were evaluated using the Mann-Whitney U test and Spearman’s Rank Correlation Coefficient, respectively. Student’s t-test compared log10-transformed signal areas for metabolomic data.

Results: Within the intervention group fecal albumin levels decreased significantly compared to the start (p = 0.027), with no significant difference between groups at the end of the trial (p = 0.28; Figure 1a). A significant association was found between the DAS28 fold change and albumin in the intervention group (r = 0.5, p < 0.001; Figure 2a). Fecal calprotectin was not significantly different between intervention and control groups at 16-weeks (p = 0.95) or within the intervention group (p = 0.12; Figure 1b). The DAS28 change was not significantly associated with calprotectin in the intervention group (Figure 2b). The major metabolite increased in the best responders to the intervention was lenticin (log2 fold change 1.32, p < 0.0001; Figure 1c). The best responders also had decreased levels of tryptophan (log2 fold change –0.12, p = 0.03; Figure 1d). Changes in lenticin and tryptophan were not correlated with changes in DAS28 (Figure 2c,d).

Conclusion: The intervention improved intestinal barrier integrity, measured with fecal albumin, increased lenticin levels and decreased tryptophan levels. Lenticin is a lentil intake biomarker shown to be protective against LPS-induced inflammation and osteoclastic differentiation,6,7 while indole, a bacterial-derived tryptophan metabolite, has been linked to experimental arthritis development.8 These preliminary findings introduce potential mechanistic pathways linking the intervention to its observed clinical effects, warranting further investigation into gut barrier integrity, microbiome, and metagenomic testing.

References (PMID):

1. 34663431
2. 36617162
3. 30111803
4. 33674813
5. 29902436
6. 28420166
7. 29136954
8. 38113112

Supporting image 1

Figure 1. Data points show individual median values of (a) fecal albumin and (b) fecal calprotectin for all participants taking part in the Plants for Joints randomized controlled trial, and (c) plasma lenticin and (d) plasma tryptophan in 30 participants with the greatest DAS28 change during the PFJ intervention and 10 control participants with the most stable DAS28 scores within the trial period. . Between group differences at the end of the intervention were assessed with a linear regression adjusted for baseline values and within group differences were assessed with a Mann Whitney U test. * = p < 0.05, ** = p < 0.01, ***= p < 0.001

Supporting image 2

Figure 2. Data points represent the fold change in DAS28 vs. fecal albumin and (b) fecal calprotectin from start to end of the Plants for Joints lifestyle intervention, and (c) plasma lenticin and (d) plasma tryptophan in 30 participants with the greatest DAS28 change during the PFJ intervention and 10 control participants with the most stable DAS28 scores within the trial period. Correlations were tested using Spearman’s rank correlation coefficient.


Disclosures: C. Wagenaar: Plants for Health B.V., 4; M. Pereira: None; S. Redanz: None; A. Gessner: None; W. Walrabenstein: Plants for Health B.V., 4; M. Kriegel: AbbVie/Abbott, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 5, Dr. Schär, 5, Eligo Biosciences, 5, Enterome, 5, Genentech, 5, GlaxoSmithKlein(GSK), 5, Maat Pharma, 5, Merck/MSD, 5, Novartis, 5, Roche, 5, Sanofi, 5; M. Zaiss: None; D. van Schaardenburg: Plants for Health B.V., 11.

To cite this abstract in AMA style:

Wagenaar C, Pereira M, Redanz S, Gessner A, Walrabenstein W, Kriegel M, Zaiss M, van Schaardenburg D. Possible Mechanistic Pathways of the Effective “Plants for Joints” Lifestyle and Dietary Intervention for Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/possible-mechanistic-pathways-of-the-effective-plants-for-joints-lifestyle-and-dietary-intervention-for-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/possible-mechanistic-pathways-of-the-effective-plants-for-joints-lifestyle-and-dietary-intervention-for-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology